The COVID-19 response makes NZ an attractive testing destination | Instant News

While the rates of COVID-19 in the US, Europe and other parts of the world are higher than those leaders might like, New Zealand’s infection and death rates are very low. Citizens can attend concerts and rugby matches without a mask, and businesses can operate without the restrictions that make travel and trade challenging in other parts of the world.

For this reason, Kiwi contract research organizations (CROs) such as Pharmaceutical Solutions (PSL) are enjoying increasing interest in their operations. Outsourcing-Pharma (OSP) recently spoke with managing director Jacquie Palmer (JP) about the phenomenon, and what it means for the future of clinical research in the region.

OSP: Could you tell us about the evolution of the clinical trials industry in New Zealand – how has it grown and changed over the years? person

JP: In terms of size, the clinical trials industry in New Zealand has been relatively stable over the last five years; recently, we have seen increased interest in NZ for early phase studies, particularly in the therapeutic fields of oncology, neurological diseases and infections. New Zealand has one of the highest rates of asthma and respiratory disease in the world and we would like to see more global trials coming into the region for this therapeutic field, where we have strong patients and top opinion leaders.

New Zealand has a strong history of conducting successful ‘rescue studies’, where recruitment has become difficult internationally and new geographic areas have to be considered. This is common in flu-like seasonal studies, where the Southern Hemisphere effectively extends the Northern Hemisphere winter and therefore the patient recruitment period is extended.


image source

to request modification Contact us at Here or [email protected]